TY - JOUR
T1 - Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
AU - Nicolini, Franck E.
AU - Mauro, Michael J.
AU - Martinelli, Giovanni
AU - Kim, Dong Wook
AU - Soverini, Simona
AU - Müller, Martin C.
AU - Hochhaus, Andreas
AU - Cortes, Jorge
AU - Chuah, Charles
AU - Dufva, Inge H.
AU - Apperley, Jane F.
AU - Yagasaki, Fumiharu
AU - Pearson, Jay D.
AU - Peter, Senaka
AU - Rodriguez, Cesar Sanz
AU - Preudhomme, Claude
AU - Giles, Francis
AU - Goldman, John M.
AU - Zhou, Wei
PY - 2009/12/17
Y1 - 2009/12/17
N2 - The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)+ acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57% cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph+ ALL patients. After T315I mutation detection, second-generation TKIs were used in 56% of cases, hydroxyurea in 39%, imatinib in 35%, cytarabine in 26%, MK-0457 in 11%, stem cell transplantation in 17%, and interferon-α in 6% of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP,AP, BP, and Ph+ ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.
AB - The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)+ acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57% cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph+ ALL patients. After T315I mutation detection, second-generation TKIs were used in 56% of cases, hydroxyurea in 39%, imatinib in 35%, cytarabine in 26%, MK-0457 in 11%, stem cell transplantation in 17%, and interferon-α in 6% of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP,AP, BP, and Ph+ ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.
UR - http://www.scopus.com/inward/record.url?scp=73949111062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73949111062&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-04-219410
DO - 10.1182/blood-2009-04-219410
M3 - Article
C2 - 19843886
AN - SCOPUS:73949111062
SN - 0006-4971
VL - 114
SP - 5271
EP - 5278
JO - Blood
JF - Blood
IS - 26
ER -